← All diseases
Brain and nervous system
Multiple sclerosis (progressive)
Do you want to receive a message when there is new research on Multiple Sclerosis (Progressive)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication you see one sentence explaining what was investigated — and you'll be notified as soon as new research on Multiple sclerosis (progressive) is published. View what Premium costs.
Publications and studies (1543)
- Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy. (2023/09/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Potential benefits of medium chain fatty acids in aging and neurodegenerative disease. (2023/08/23) ♡
- Use of Telemedicine Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic. (2023/08/01) ♡
- Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis. (2023/08/01) ♡
- Primary lateral sclerosis natural history study - planning, designing, and early enrollment. (2023/08/01) ♡
- Sex-dependent expression levels of VAV1 and P2X7 in PBMC of multiple sclerosis patients. (2023/08/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Development of a Long-Term Cross-Sectoral Case and Care Management Manual for Patients With Severe Multiple Sclerosis and Their Caregivers. (2023/07/01) ♡
- Higher diet quality is associated with short and long-term benefits on SF-6D health state utilities: a 5-year cohort study in an international sample of people with multiple sclerosis. (2023/07/01) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The Role of Gut Microbiome in the Pathogenesis of Multiple Sclerosis and Related Disorders. (2023/06/30) ♡
- Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study. (2023/06/01) ♡
- Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis. (2023/06/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis. (2023/05/01) ♡
- Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry. (2023/05/01) ♡
- Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study. (2023/05/01) ♡
- Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis. (2023/05/01) ♡
- Waterpipe and cigarette smoking and drug and alcohol consumption, and the risk of primary progressive multiple sclerosis: A population-based case-control study. (2023/04/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Repurposing artemisinins as neuroprotective agents: a focus on the PI3k/Akt signalling pathway. (2023/04/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. It is time to define cognitive phenotypes in multiple sclerosis. (2023/04/01) ♡
- Enlarged choroid plexus related to cortical atrophy in multiple sclerosis. (2023/04/01) ♡
- Adipokines in multiple sclerosis patients are related to clinical and radiological measures. (2023/04/01) ♡
- CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS. (2023/04/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report. (2023/04/01) ♡
- Blocking the IFN-gamma signal in the choroid plexus confers resistance to experimental autoimmune encephalomyelitis. (2023/04/01) ♡
- Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma. (2023/04/01) ♡
- Diet, Physical Activity, and Stress Among Wheelchair Users With Multiple Sclerosis: Examining Individual and Co-Occurring Behavioral Risk Factors. (2023/04/01) ♡
- Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. (2023/03/14) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Death following rapidly progressive demyelinating disorder in a young female-a case report. (2023/03/01) ♡
- Prevalence and determinants of language impairment in non-demented amyotrophic lateral sclerosis patients. (2023/03/01) ♡
- Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. (2023/03/01) ♡
- Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis. (2023/03/01) ♡
- The expression profile of HAR1A and HAR1B in the peripheral blood cells of multiple sclerosis patients. (2023/03/01) ♡
- Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis. (2023/03/01) ♡
- Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis. (2023/03/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Progressive Systemic Sclerosis With Negative Antinuclear Antibodies and Absence of Raynaud's Phenomenon: A Case Report and Literature Review. (2023/03/01) ♡
- Brain Atrophy and Physical and Cognitive Disability in Multiple Sclerosis. (2023/03/01) ♡
- Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis. (2023/02/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases. (2023/02/20) ♡
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. (2023/02/01) ♡
- Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. (2023/02/01) ♡
- External validation of a clinical prediction model in multiple sclerosis. (2023/02/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis. (2023/02/01) ♡
- Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis. (2023/02/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. (2023/02/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Neuronal deletion of MnSOD in mice leads to demyelination, inflammation and progressive paralysis that mimics phenotypes associated with progressive multiple sclerosis. (2023/02/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Effects of Palliative Care for Progressive Neurologic Diseases: A Systematic Review and Meta-Analysis. (2023/02/01) ♡
- Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. (2023/02/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis. (2023/02/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study. (2023/02/01) ♡
- Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. (2023/02/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Brain-derived neurotrophic factor, neurofilament light and glial fibrillary acidic protein do not change in response to aerobic training in people with MS-related fatigue - a secondary analysis of a randomized controlled trial. (2023/02/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.